SynthesisBMC surgery2026
Efficacy of tranexamic acid for prevention of heterotopic ossification after orthopedic surgery: a systematic review and meta-analysis.
Synthesis in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo systematically evaluate the effect of tranexamic acid (TXA) on the incidence of heterotopic ossification (HO) following orthopedic surgery.
methodsA Systematic review and Meta-analysis was carried out according to PRISMA guidelines. PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials were searched from inception date to October 15, 2025. Randomized controlled trials (RCTs) and observational studies comparing TXA with control (placebo or no TXA) in patients undergoing orthopaedic surgery who reported rates of HO were included. Data were pooled using a random-effects model, and subgroup and sensitivity analyses were performed.
resultsSix studies involving 1456 patients (TXA = 778, Control = 678) were included. All included studies reported HO outcomes. When stratified by study design, pooled analysis of randomized controlled trials (RCTs) showed no significant reduction in HO incidence with TXA (OR = 0.92, 95% CI 0.11-7.77; I
conclusionsCurrent evidence does not demonstrate a statistically significant reduction in heterotopic ossification with tranexamic acid based on randomized data. Although observational studies suggest a potential association, this finding may be influenced by confounding and should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.